CR20180029A - POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES - Google Patents
POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASESInfo
- Publication number
- CR20180029A CR20180029A CR20180029A CR20180029A CR20180029A CR 20180029 A CR20180029 A CR 20180029A CR 20180029 A CR20180029 A CR 20180029A CR 20180029 A CR20180029 A CR 20180029A CR 20180029 A CR20180029 A CR 20180029A
- Authority
- CR
- Costa Rica
- Prior art keywords
- interleucine
- receiver
- inflammatory diseases
- treat inflammatory
- potential inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
La presente invención proporciona inhibidores peptídicos novedosos del receptor de interleucina 23 y composiciones y métodos relacionados para utilizar estos inhibidores peptídicos para el tratamiento o la prevención de diversas enfermedades y trastornos, incluidas enfermedades intestinales inflamatoriasThe present invention provides novel peptide inhibitors of interleukin 23 and related compositions and methods for using these peptide inhibitors for the treatment or prevention of various diseases and disorders, including inflammatory bowel diseases.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 | |
| PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180029A true CR20180029A (en) | 2018-06-05 |
Family
ID=57757647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180029A CR20180029A (en) | 2015-07-15 | 2016-07-15 | POTENTIAL INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (en) |
| JP (1) | JP6858174B2 (en) |
| KR (1) | KR102513978B1 (en) |
| CN (1) | CN108348580B (en) |
| AU (1) | AU2016293619B2 (en) |
| BR (1) | BR112018000691A2 (en) |
| CA (1) | CA2991984A1 (en) |
| CL (3) | CL2018000128A1 (en) |
| CO (1) | CO2018000349A2 (en) |
| CR (1) | CR20180029A (en) |
| DO (1) | DOP2018000010A (en) |
| EA (1) | EA035733B9 (en) |
| EC (1) | ECSP18002929A (en) |
| HK (2) | HK1257747A1 (en) |
| IL (1) | IL256827A (en) |
| MX (1) | MX2018000542A (en) |
| NI (1) | NI201800008A (en) |
| PE (1) | PE20180571A1 (en) |
| PH (1) | PH12018500086A1 (en) |
| SG (1) | SG10201912066SA (en) |
| SV (1) | SV2018005614A (en) |
| UA (1) | UA123772C2 (en) |
| WO (1) | WO2017011820A2 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3176170T (en) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Substituted tricyclic compounds as fgfr inhibitors |
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| PE20152033A1 (en) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | BICYCLE HETEROCYCLES AS FGFR INHIBITORS |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| KR102482790B1 (en) | 2014-07-17 | 2022-12-29 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| MX2017004300A (en) | 2014-10-01 | 2017-12-18 | Protagonist Therapeutics Inc | NOVEL A4ß7 PEPTIDE MONOMER AND DIMER ANTAGONISTS. |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US10407468B2 (en) | 2016-03-23 | 2019-09-10 | Protagonist Therapeutics, Inc. | Methods for synthesizing α4β7 peptide antagonists |
| EP3570864A4 (en) * | 2017-01-18 | 2020-12-30 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
| CN112867716A (en) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Solid forms of FGFR inhibitors and methods for their preparation |
| TW202019948A (en) * | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| CN110015978B (en) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN114341161A (en) * | 2019-07-10 | 2022-04-12 | 领导医疗有限公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| JOP20220083A1 (en) | 2019-10-14 | 2023-01-30 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP3819307A1 (en) | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4090670A1 (en) | 2020-01-15 | 2022-11-23 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| JP7397239B2 (en) * | 2020-11-20 | 2023-12-12 | ヤンセン ファーマシューティカ エヌ．ベー． | Compositions of peptide inhibitors of interleukin-23 receptors |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| AU2022310347A1 (en) * | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Bicyclic peptide inhibitors of interleukin-23 receptor |
| TW202332682A (en) | 2021-12-01 | 2023-08-16 | 丹麥商西蘭製藥公司 | Peptide inhibitors of interleukin-23 receptor |
| WO2023172648A2 (en) * | 2022-03-09 | 2023-09-14 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (en) * | 2022-03-17 | 2023-11-07 | 北京大学 | Staple peptide, preparation method and pharmaceutical application thereof |
| WO2024003313A1 (en) | 2022-06-30 | 2024-01-04 | Sanofi | New peptides as selective il-23 receptor antagonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| KR20090119876A (en) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon/glp-1 receptor co-agonists |
| EP2288621A4 (en) * | 2007-07-06 | 2012-01-04 | Valorisation Hsj Soc En Commandite | Il-23 receptor antagonists and uses thereof |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US9523073B2 (en) | 2010-03-31 | 2016-12-20 | Medical Diagnostic Laboratories, Llc | Elisa for a naturally-occurring soluble truncated form of IL-23 receptor |
| US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US8946150B2 (en) | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| CA2926685A1 (en) * | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| KR102482790B1 (en) | 2014-07-17 | 2022-12-29 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
-
2016
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/en active IP Right Grant
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/en active Active
- 2016-07-15 UA UAA201801482A patent/UA123772C2/en unknown
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/en unknown
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/en unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/en active Active
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/en active Search and Examination
- 2016-07-15 CR CR20180029A patent/CR20180029A/en unknown
- 2016-07-15 EA EA201890325A patent/EA035733B9/en not_active IP Right Cessation
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en active Pending
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/en unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/en unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/en unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/en unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/en unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/en unknown
-
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/en unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/en unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2018000010A (en) | PEPTIDE INHIBITORS OF THE INTERLEUCINE RECEIVER 23 AND ITS USE TO TREAT INFLAMMATORY DISEASES | |
| EA201891199A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890048A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890047A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201891202A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201891201A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| GT201600233A (en) | COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER | |
| EA201890050A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890049A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201890051A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201792047A1 (en) | NEW CONNECTIONS | |
| AR119389A1 (en) | INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
| EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA201692529A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS USING FOLLYSTATINE POLYPEPTIDES | |
| UY37018A (en) | PAD4 BICYCLIC INHIBITORS | |
| BR112022000328A2 (en) | Interleukin-23 receptor peptide inhibitors and their use to treat inflammatory diseases | |
| UA123202C2 (en) | Antibodies to tau and uses thereof | |
| MX2020006365A (en) | Quinazolinones as parp14 inhibitors. | |
| EA201692313A1 (en) | Derivatives of indolysine as inhibitors of phosphosinositide-3-kinase | |
| EA201692091A1 (en) | CHINOXALINE COMPOUNDS AND THEIR APPLICATION | |
| BR112017008045A2 (en) | compounds as nik inhibitors | |
| EA201792604A1 (en) | AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS | |
| UY37017A (en) | AZA-BENCIMIDAZOL INHIBITORS OF PAD4 | |
| CL2016002321A1 (en) | Compounds derived from 2-8-5-chloropyrimidin-2-ylamino-6,7,8,9-tetrahydro-5h-pyrido3,2-bindol-5-ylacetic acid, modulators of the prostaglandin d2 receptor pharmaceutical composition and its use for the treatment of diseases allergic immune disorders. |